Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avivagen Inc V.VIV.H

Alternate Symbol(s):  VIVXF

Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.


TSXV:VIV.H - Post by User

Bullboard Posts
Post by MineDiggeron Feb 22, 2013 8:42am
149 Views
Post# 21027614

Outlook

Outlook

So having lost a little in 2010/11 when TechnicalBuy had this (CFR) as a pick, I'm curious about the 60-70c mentioned of late:

  • "Ultimately, I agree with the 60-70 cent target [jdstox].  I'd say December 2013 for that, but it's just a guess. " [smallcaplover]
  • "The company update at the end of January  did not indicate to me that anything regarding their products were going to come to fruition this year." [woundedknee]
  • "With successful completion of current partnership initiatives in international markets, we have targeted breakeven in 2013 and profitability in 2014." [David Hankinson CEO on stockhouse (as client), 2012-03-08]

2012 ended with 96.7 + 40.5 shares, implying 2013 ending with 80-100m cap and the CEO not yet expecting to be making a profit (and who ever arrives on time with financial+s).

Isn't this valuation going to take a lot of collective belief in future rather than past performance. And how much cash will have to be raised before (or after) cf+?

But I can see that antibiotic growth promotion alternatives look attractive, not an area I understand though, and I thought they had already been banned.

MD

Bullboard Posts